Morris Grant D09CA-082 (discontinued)

This study has been discontinued by the researcher due to undesirable effects on the patient.  SCARF has redirected the funding to study D09CA-029.

Lymphoma is one of the most common and fatal cancers in dogs. Most dogs treated with chemotherapy go into remission, but the cancer quickly develops drug resistance and recurs. Chemotherapy generally works by initiating apoptosis, a normal process in which cells undergo programmed death. Apoptosis occurs throughout life and is critical for developing and maintaining healthy tissues, but cancer cells develop ways to avoid apoptosis, which allows them to grow and survive in an uncontrolled fashion. Researchers will study a novel compound, PAC-1, that has been shown to induce apoptosis in tumor cells without the presence of chemotherapy. This study will evaluate the safety, dosing and efficacy of PAC-1 in dogs with lymphoma.